Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

BACKGROUND: Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response rate in the first patients, who received a therapy with Lu-PS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EJNMMI Res
Main Authors: Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Kürpig, Stefan, Bögemann, Martin, Claesener, Michael, Eppard, Elisabeth, Gärtner, Florian, Rogenhofer, Sebastian, Schäfers, Michael, Essler, Markus
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477007/
https://ncbi.nlm.nih.gov/pubmed/26099227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-015-0114-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados